Literature DB >> 33598810

Psoriatic arthritis associated with peliosis hepatis: characteristics and therapeutic management.

Maroua Slouma1,2, Yasmine Khrifech3,4, Rim Dhahri3,4, Emna Hannech3,4, Zeineb Tayeb4,5, Amen Ghozzi4,6, Leila Metoui3,4, Imen Gharsallah3,4, Bassem Louzir4,7.   

Abstract

Peliosis hepatis is characterized by hepatic sinusoidal dilatation and multiple blood-filled cystic cavities within the liver parenchyma. It can be due to infectious diseases, immunological disorders, neoplasia, and the use of various kinds of drugs. We presented the case of a nonsmoker 55-year-old man who complained about a 5-month history of arthritis. Medical history was consistent with psoriasis and hypertension. He denied any drug use or alcohol consumption. Physical examination showed extended psoriatic lesions. He had arthritis of the knees, ankles, wrists, and elbows. His body mass index was 22 kg/m2. Laboratory findings revealed an increased serum gamma-glutamyl transferase level (1014 UI/L, normal value (N) 11-55) and total alkaline phosphatase (278 U/L, N 30-171). Hepatitis A, B, and C serologic test results were negative. Anti-nuclear antibodies, anti-Ro/SSA, anti-GP210, anti-SP100, anti-SLA, anti-LKM1, anti-M2, anti-LC1, and anti-PML were also negative. Histopathological examination of a liver biopsy specimen revealed peliosis hepatis.The pelvic radiograph showed bilateral ankylosis of sacroiliac joints. Hand and foot radiographs showed periosteal bone apposition. The diagnosis of psoriatic arthritis associated with peliosis hepatis was made. The patient received infliximab (5 mg/kg) with a significant improvement after 3 months of follow-up. Peliosis hepatis should be considered as a possible etiology of liver enzyme abnormalities in patients with psoriatic arthritis. We highlighted the effectiveness and safety of the TNF inhibitors in the treatment of peliosis hepatis associated with psoriatic arthritis. Key Points • Peliosis hepatis should be considered as a possible etiology of liver enzyme disturbance in patients with psoriatic arthritis. • Special caution should be advised in the management of psoriatic arthritis associated with peliosis hepatis to avoid the worsening of liver function. • Infliximab is suggested as a possible treatment of peliosis hepatis associated with psoriatic arthritis.

Entities:  

Keywords:  Infliximab; Peliosis hepatis; Psoriatic arthritis

Year:  2021        PMID: 33598810     DOI: 10.1007/s10067-021-05647-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  21 in total

1.  Peliosis hepatis.

Authors:  F G ZAK
Journal:  Am J Pathol       Date:  1950-01       Impact factor: 4.307

2.  Classification criteria for psoriatic arthritis: development of new criteria from a large international study.

Authors:  William Taylor; Dafna Gladman; Philip Helliwell; Antonio Marchesoni; Philip Mease; Herman Mielants
Journal:  Arthritis Rheum       Date:  2006-08

3.  Intravenous immunoglobulin therapy in an infant with autoimmune hemolytic anemia associated with necrotic hepatitis and peliosis.

Authors:  A Lachaux; Y Bertrand; R Bouvier; C Dumont; M Pinzaru; M Hermier
Journal:  J Pediatr Gastroenterol Nutr       Date:  1996-01       Impact factor: 2.839

4.  Hepatosplenic peliosis after danazol and glucocorticoids for ITP.

Authors:  G Nesher; L Dollberg; A Zimran; C Hershko
Journal:  N Engl J Med       Date:  1985-01-24       Impact factor: 91.245

5.  Hepatic vascular disease after kidney transplantation: report of two cases and review of the literature.

Authors:  M Adler; M Delhaye; C Deprez; N Hardy; M Gelin; L De Pauw; P Vereerstraeten; M Cremer; C Toussaint
Journal:  Nephrol Dial Transplant       Date:  1987       Impact factor: 5.992

Review 6.  Bartonella infection: treatment and drug resistance.

Authors:  Silpak Biswas; Jean-Marc Rolain
Journal:  Future Microbiol       Date:  2010-11       Impact factor: 3.165

7.  Laparoscopic study of peliosis hepatis and nodular transformation of the liver before and after renal transplantation: natural history and aetiology in follow-up cases.

Authors:  S Izumi; M Nishiuchi; Y Kameda; S Nagano; T Fukunishi; T Kohro; Y Shinji
Journal:  J Hepatol       Date:  1994-01       Impact factor: 25.083

8.  The liver in systemic lupus erythematosus: pathologic analysis of 52 cases and review of Japanese Autopsy Registry Data.

Authors:  T Matsumoto; T Yoshimine; K Shimouchi; H Shiotu; N Kuwabara; Y Fukuda; T Hoshi
Journal:  Hum Pathol       Date:  1992-10       Impact factor: 3.466

Review 9.  Peliosis hepatis: Personal experience and literature review.

Authors:  Daniele Crocetti; Andrea Palmieri; Giuseppe Pedullà; Vittorio Pasta; Valerio D'Orazi; Gian Luca Grazi
Journal:  World J Gastroenterol       Date:  2015-12-14       Impact factor: 5.742

10.  Peliosis hepatis presenting with massive hepatomegaly in a patient with idiopathic thrombocytopenic purpura.

Authors:  Sun Bean Kim; Do Kyung Kim; Sun Jeong Byun; Ji Hye Park; Jin Young Choi; Young Nyun Park; Do Young Kim
Journal:  Clin Mol Hepatol       Date:  2015-12-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.